Pretransplant immunomodulation of highly sensitized small bowel transplant candidates with intravenous immune globulin

Gabriel Gondolesi, Benoit Blondeau, Raphael Maurette, Laura Hoppenhauer, Gonzalo Rodriguez-Laiz, Thomas Schiano, Peter Boros, Jonathan Bromberg, Enver Akalin, Bernhard Sauter

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Presence of preformed lymphocytotoxic antibodies may represent a barrier to isolated intestinal transplantation (IITx). We developed an intravenous immunoglobulins (IVIg) based desensitization protocol for candidates with high panel-reactive antibodies (PRA). Six patients with a mean PRA of 72±22% were included in a four-level (L) protocol with escalating doses of IVIg (L1, L2), addition of mycophenolate mofetil (MMF) or plasmapheresis (L3); and anti-CD20 (Rituximab) (L4). Four of six candidates improved their PRAs (from a mean of 66.2% to 25.5%; P=0.01) and were successfully transplanted. At a mean follow-up of 8 months, number and severity of rejection episodes of protocol patients did not differ from patients with low PRA transplanted during the same period. These data support the use of IVIg to desensitize patients waiting for IITx. It increases the applicability of IITx, and reduces the waiting time and mortality on the waiting list with outcomes comparable to nonsensitized recipients.

Original languageEnglish (US)
Pages (from-to)1743-1746
Number of pages4
JournalTransplantation
Volume81
Issue number12
DOIs
StatePublished - Jun 2006
Externally publishedYes

Fingerprint

Immunomodulation
Intravenous Immunoglobulins
Transplants
Antibodies
Mycophenolic Acid
Antilymphocyte Serum
Waiting Lists
Plasmapheresis
Transplantation
Mortality

Keywords

  • Alloimmunization
  • Immunoglobulins
  • Intestinal transplantation

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Gondolesi, G., Blondeau, B., Maurette, R., Hoppenhauer, L., Rodriguez-Laiz, G., Schiano, T., ... Sauter, B. (2006). Pretransplant immunomodulation of highly sensitized small bowel transplant candidates with intravenous immune globulin. Transplantation, 81(12), 1743-1746. https://doi.org/10.1097/01.tp.0000226078.94635.76

Pretransplant immunomodulation of highly sensitized small bowel transplant candidates with intravenous immune globulin. / Gondolesi, Gabriel; Blondeau, Benoit; Maurette, Raphael; Hoppenhauer, Laura; Rodriguez-Laiz, Gonzalo; Schiano, Thomas; Boros, Peter; Bromberg, Jonathan; Akalin, Enver; Sauter, Bernhard.

In: Transplantation, Vol. 81, No. 12, 06.2006, p. 1743-1746.

Research output: Contribution to journalArticle

Gondolesi, G, Blondeau, B, Maurette, R, Hoppenhauer, L, Rodriguez-Laiz, G, Schiano, T, Boros, P, Bromberg, J, Akalin, E & Sauter, B 2006, 'Pretransplant immunomodulation of highly sensitized small bowel transplant candidates with intravenous immune globulin', Transplantation, vol. 81, no. 12, pp. 1743-1746. https://doi.org/10.1097/01.tp.0000226078.94635.76
Gondolesi, Gabriel ; Blondeau, Benoit ; Maurette, Raphael ; Hoppenhauer, Laura ; Rodriguez-Laiz, Gonzalo ; Schiano, Thomas ; Boros, Peter ; Bromberg, Jonathan ; Akalin, Enver ; Sauter, Bernhard. / Pretransplant immunomodulation of highly sensitized small bowel transplant candidates with intravenous immune globulin. In: Transplantation. 2006 ; Vol. 81, No. 12. pp. 1743-1746.
@article{bf7deb2a7d47499ea3dc3256629071d4,
title = "Pretransplant immunomodulation of highly sensitized small bowel transplant candidates with intravenous immune globulin",
abstract = "Presence of preformed lymphocytotoxic antibodies may represent a barrier to isolated intestinal transplantation (IITx). We developed an intravenous immunoglobulins (IVIg) based desensitization protocol for candidates with high panel-reactive antibodies (PRA). Six patients with a mean PRA of 72±22{\%} were included in a four-level (L) protocol with escalating doses of IVIg (L1, L2), addition of mycophenolate mofetil (MMF) or plasmapheresis (L3); and anti-CD20 (Rituximab) (L4). Four of six candidates improved their PRAs (from a mean of 66.2{\%} to 25.5{\%}; P=0.01) and were successfully transplanted. At a mean follow-up of 8 months, number and severity of rejection episodes of protocol patients did not differ from patients with low PRA transplanted during the same period. These data support the use of IVIg to desensitize patients waiting for IITx. It increases the applicability of IITx, and reduces the waiting time and mortality on the waiting list with outcomes comparable to nonsensitized recipients.",
keywords = "Alloimmunization, Immunoglobulins, Intestinal transplantation",
author = "Gabriel Gondolesi and Benoit Blondeau and Raphael Maurette and Laura Hoppenhauer and Gonzalo Rodriguez-Laiz and Thomas Schiano and Peter Boros and Jonathan Bromberg and Enver Akalin and Bernhard Sauter",
year = "2006",
month = "6",
doi = "10.1097/01.tp.0000226078.94635.76",
language = "English (US)",
volume = "81",
pages = "1743--1746",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Pretransplant immunomodulation of highly sensitized small bowel transplant candidates with intravenous immune globulin

AU - Gondolesi, Gabriel

AU - Blondeau, Benoit

AU - Maurette, Raphael

AU - Hoppenhauer, Laura

AU - Rodriguez-Laiz, Gonzalo

AU - Schiano, Thomas

AU - Boros, Peter

AU - Bromberg, Jonathan

AU - Akalin, Enver

AU - Sauter, Bernhard

PY - 2006/6

Y1 - 2006/6

N2 - Presence of preformed lymphocytotoxic antibodies may represent a barrier to isolated intestinal transplantation (IITx). We developed an intravenous immunoglobulins (IVIg) based desensitization protocol for candidates with high panel-reactive antibodies (PRA). Six patients with a mean PRA of 72±22% were included in a four-level (L) protocol with escalating doses of IVIg (L1, L2), addition of mycophenolate mofetil (MMF) or plasmapheresis (L3); and anti-CD20 (Rituximab) (L4). Four of six candidates improved their PRAs (from a mean of 66.2% to 25.5%; P=0.01) and were successfully transplanted. At a mean follow-up of 8 months, number and severity of rejection episodes of protocol patients did not differ from patients with low PRA transplanted during the same period. These data support the use of IVIg to desensitize patients waiting for IITx. It increases the applicability of IITx, and reduces the waiting time and mortality on the waiting list with outcomes comparable to nonsensitized recipients.

AB - Presence of preformed lymphocytotoxic antibodies may represent a barrier to isolated intestinal transplantation (IITx). We developed an intravenous immunoglobulins (IVIg) based desensitization protocol for candidates with high panel-reactive antibodies (PRA). Six patients with a mean PRA of 72±22% were included in a four-level (L) protocol with escalating doses of IVIg (L1, L2), addition of mycophenolate mofetil (MMF) or plasmapheresis (L3); and anti-CD20 (Rituximab) (L4). Four of six candidates improved their PRAs (from a mean of 66.2% to 25.5%; P=0.01) and were successfully transplanted. At a mean follow-up of 8 months, number and severity of rejection episodes of protocol patients did not differ from patients with low PRA transplanted during the same period. These data support the use of IVIg to desensitize patients waiting for IITx. It increases the applicability of IITx, and reduces the waiting time and mortality on the waiting list with outcomes comparable to nonsensitized recipients.

KW - Alloimmunization

KW - Immunoglobulins

KW - Intestinal transplantation

UR - http://www.scopus.com/inward/record.url?scp=33745446460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745446460&partnerID=8YFLogxK

U2 - 10.1097/01.tp.0000226078.94635.76

DO - 10.1097/01.tp.0000226078.94635.76

M3 - Article

C2 - 16794543

AN - SCOPUS:33745446460

VL - 81

SP - 1743

EP - 1746

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 12

ER -